“Golgi-customized Trojan horse” nanodiamonds impair GLUT1 plasma membrane localization and inhibit tumor glycolysis
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.05.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Bei Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China. Hauptthemen laut MEDLINE: Glycolysis, Golgi Apparatus, Cell Membrane, Glucose Transporter Type 1. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Young Elite Scientists Sponsorship Program by Tianjin, National Natural Science Foundation of China, Grantová Agentura České Republiky.
Abstract (Originalsprache)
Nutrient or energy deprivation, especially glucose restriction, is a promising anticancer therapeutic approach. However, establishing a precise and potent deprivation strategy remains a formidable task. The Golgi morphology is crucial in maintaining the function of transport proteins (such as GLUT1) driving glycolysis. Thus, in this study, we present a "Golgi-customized Trojan horse" based on tellurium loaded with apigenin (4',5,7-trihydroxyflavone) and human serum albumin, which was able to induce GLUT1 plasma membrane localization disturbance via Golgi dispersal leading to the inhibition of tumor glycolysis. Diamond-shaped delivery system can efficiently penetrate into cells as a gift like Trojan horse, which decomposes into tellurite induced by intrinsically high H2O2 and GSH levels. Consequently, tellurite acts as released warriors causing up to 3.8-fold increase in Golgi apparatus area due to the down-regulation of GOLPH3. Further, this affects GLUT1 membrane localization and glucose transport disturbance. Simultaneously, apigenin hinders ongoing glycolysis and causes significant decrease in ATP level. Collectively, our "Golgi-customized Trojan horse" demonstrates a potent antitumor activity because of its capability to deprive energy resources of cancer cells. This study not only expands the applications of tellurium-based nanomaterials in the biomedicine but also provides insights into glycolysis restriction for anticancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Key Laboratory of Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
- Department of Chemistry and Biochemistry, Mendel University in Brno, CZ-61300 Brno, Czech Republic.
- Tianjin Key Laboratory of Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China. Electronic address: linan1985@tju.edu.cn.
Förderung
- Young Elite Scientists Sponsorship Program by Tianjin
- National Natural Science Foundation of China
- Grantová Agentura České Republiky
- National Key Research and Development Program of China
Zitieren
APA
Kang, B., Wang, H., Jing, H., Dou, Y., Krizkova, S., Heger, Z., Adam, V., & Li, N. (2024). “Golgi-customized Trojan horse” nanodiamonds impair GLUT1 plasma membrane localization and inhibit tumor glycolysis. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.05.025
Vancouver
Kang B, Wang H, Jing H, Dou Y, Krizkova S, Heger Z, et al. “Golgi-customized Trojan horse” nanodiamonds impair GLUT1 plasma membrane localization and inhibit tumor glycolysis. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.05.025
BibTeX
@article{Kang2024,
author = {Kang, Bei and Wang, Haobo and Jing, Huaqing and Dou, Yunsheng and Krizkova, Sona and Heger, Zbynek and Adam, Vojtech and Li, Nan},
title = {“Golgi-customized Trojan horse” nanodiamonds impair GLUT1 plasma membrane localization and inhibit tumor glycolysis},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.05.025}
}
EUVIMED